Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Trading 04-20 13:59:40 EDT

29.38

-0.45

-1.53%

High29.88	Low29.33	Vol2.38M
Open29.74	D1 Closing29.83	Amplitude1.84%
Mkt Cap21.02B	Tradable Cap13.72B	Total Shares715.70M
T/O70.29M	T/O Rate0.51%	Tradable Shares467.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":29.375,"timestamp":1776707973646,"preClose":29.83,"halted":0,"volume":2375873,"delay":0,"changeRate":-0.015253100905129009,"floatShares":467000000,"shares":715701137,"eps":-1.173433,"marketStatus":"Trading","change":-0.455,"latestTime":"04-20 13:59:40 EDT","open":29.74,"high":29.88,"low":29.33,"amount":70292678.364666,"amplitude":0.018438,"askPrice":29.38,"askSize":702,"bidPrice":29.37,"bidSize":423,"shortable":3,"etf":0,"ttmEps":-1.173433,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776715200000},"marketStatusCode":2,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":29.83,"preHourTrading":{"tag":"盘前","latestPrice":29.83,"preClose":29.83,"latestTime":"09:28 EDT","volume":92,"amount":2735.666736,"timestamp":1776691680049,"change":0,"changeRate":0,"amplitude":0.009387},"postHourTrading":{"tag":"盘后","latestPrice":29.88,"preClose":29.83,"latestTime":"19:53 EDT","volume":649955,"amount":19388248.99,"timestamp":1776469985388,"change":0.05,"changeRate":0.001676,"amplitude":0.012404},"volumeRatio":0.743322,"impliedVol":0.4708,"impliedVolPercentile":0.8406},"requestUrl":"/m/hq/s/ROIV/tweets","defaultTab":"tweets","newsList":[{"id":"2628434730","title":"Roivant Sciences (ROIV) Gets a Buy from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2628434730","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628434730?lang=en_us&edition=fundamental","pubTime":"2026-04-18 20:17","pubTimestamp":1776514651,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Cheng from J.P. Morgan maintained a Buy rating on Roivant Sciences, with a price target of $35.00. The compan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-gets-a-buy-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-gets-a-buy-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1244550577.SGD","LU0267386448.USD","LU0225283273.USD","LU1732800096.USD","BK4588","LU2028103732.USD","LU0158827948.USD","LU0528227936.USD","LU1791710400.SGD","LU1720051108.HKD","IE00BZ1G4Q59.USD","BK4585","LU2089284900.SGD","LU0557290698.USD","LU1548497426.USD","IE00BKVL7J92.USD","LU2111349929.HKD","LU2347655156.SGD","LU2357305700.SGD","LU0098860793.USD","LU0314104364.USD","LU1989772840.SGD","LU0795875169.SGD","LU1363072403.SGD","BK4139","ROIV","LU0158827781.USD","LU2023251221.USD","BK4127","LU1244550221.USD","LU0912757837.SGD","LU1162221912.USD","BK4007","LU1244550494.USD","LU1720051017.SGD","LU1989772923.USD","LU0106831901.USD","LU0006306889.USD","LU0795875086.SGD","LU1791710582.SGD","BK4581","LU1074936037.SGD","LU1732799900.SGD","BK4504","LU0971096721.USD","LU0234570918.USD","LU0882574139.USD","LU2089283258.USD","LU2271345857.HKD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628009210","title":"Roivant Sciences Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2628009210","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628009210?lang=en_us&edition=fundamental","pubTime":"2026-04-17 01:37","pubTimestamp":1776361020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2026 13:37 ET (17:37 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627500542","title":"Roivant Sciences Ltd : Piper Sandler Raises Target Price to $40 From $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2627500542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627500542?lang=en_us&edition=fundamental","pubTime":"2026-04-16 11:02","pubTimestamp":1776308523,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Y0Q8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626456341","title":"Roivant Chief Accounting Officer Jennifer Humes disposes 13,538 shares for $384,278","url":"https://stock-news.laohu8.com/highlight/detail?id=2626456341","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626456341?lang=en_us&edition=fundamental","pubTime":"2026-04-11 06:01","pubTimestamp":1775858465,"startTime":"0","endTime":"0","summary":"Roivant Sciences Chief Accounting Officer Jennifer Humes sold 13,538 common shares on April 8, 2026.Sale priced at USD 28.37 per share on weighted-average basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL5PxvDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Chief Accounting Officer Jennifer Humes disposes 13,538 shares for $384,278","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625495186","title":"Roivant Sciences price target raised to $34 from $30 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2625495186","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625495186?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:34","pubTimestamp":1775572453,"startTime":"0","endTime":"0","summary":"Jefferies analyst Dennis Ding raised the firm’s price target on Roivant Sciences (ROIV) to $34 from $30 and keeps a Buy rating on the shares. A key...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-34-from-30-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-34-from-30-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624694383","title":"Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial Updates - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624694383","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624694383?lang=en_us&edition=fundamental","pubTime":"2026-04-04 15:17","pubTimestamp":1775287059,"startTime":"0","endTime":"0","summary":"In early April 2026, Roivant Sciences reported mixed clinical updates, including Priovant’s launch of a Phase 2b/3 brepocitinib trial in lichen planopilaris and Immunovant’s Phase 3 batoclimab thyroid eye disease studies not meeting their primary endpoint.\nThe brepocitinib program now spans four late-stage indications and has Priority Review for dermatomyositis, underscoring Roivant’s emphasis on high-need autoimmune conditions despite setbacks for batoclimab.\nWe’ll now examine how the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-68-after-mixed-autoimmune-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-68-after-mixed-autoimmune-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARTY","BK4007","BK4139","BK4587","AIYY","ROIV","BK4543","BK4585","BK4023","BK4528","BK4588","BK4551","CHAT","AGIX","AIPO","AI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664954","title":"Immunovant CEO Eric Venker disposes of common shares worth $8.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664954","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664954?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:33","pubTimestamp":1775248420,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker reported acquisition of 368,750 common shares on April 1, 2026.Disposals totaled 349,189 common shares on April 1-2, 2026 at prices of $24.04-$25.10 per share.Directly owned common shares stood at 19,561 following transactions.Derivative holdings included 1,106,250 capped value appreciation rights after transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL60pZnM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","BK4139","ROIV","IMVT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624863116","title":"Ro says working with Eli Lilly to launch Zepbound KwikPen","url":"https://stock-news.laohu8.com/highlight/detail?id=2624863116","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624863116?lang=en_us&edition=fundamental","pubTime":"2026-04-03 01:12","pubTimestamp":1775149939,"startTime":"0","endTime":"0","summary":"Direct-to-patient healthcare company Ro announced that it is working with Eli Lilly (LLY) to launch the recently FDA-approved Zepbound KwikPen nati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ro-says-working-with-eli-lilly-to-launch-zepbound-kwikpen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":"80f30c1ff97a0a0fa49b25c6b2ccdaf7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ro-says-working-with-eli-lilly-to-launch-zepbound-kwikpen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1551013342.USD","LU2236285917.USD","ELIL","LU0353189763.USD","SG9999014898.SGD","LU1064131342.USD","LU1551013425.SGD","LU0316494557.USD","IE00B1XK9C88.USD","LU0097036916.USD","GB00BDT5M118.USD","LU1629891620.HKD","LU2168564149.EUR","LU2237443978.SGD","LU2750360997.AUD","VHT","LU0683600562.USD","LU2491049909.HKD","BK4007","LU2471134523.USD","LU2237443382.USD","LU1868837136.USD","LU2552382058.USD","IE00BKPKM429.USD","LU0256863902.USD","LU1814569148.SGD","IE00B7KXQ091.USD","LU2023251221.USD","LU2324357040.USD","LU2089284900.SGD","IE00B4JS1V06.HKD","LU2361044949.HKD","LU1983299246.USD","LU1917777945.USD","LU2111349929.HKD","LU0061475181.USD","LU2357305700.SGD","LU2417539215.USD","LU2168564222.USD","LU2756315318.SGD","LU0964807845.USD","LU2023250330.USD","LLYX","LU0238689110.USD","LU2108987350.USD","LU0109394709.USD","LLYZ","LU0882574055.USD","ELIS","LU2746668974.SGD","LU2063271972.USD","LU2211815571.USD","LLII","LU0320765992.SGD","LU1127390331.HKD","LU0198837287.USD","SG9999015952.SGD","LU0889565916.HKD","SG9999018865.SGD","LU0289739699.SGD","LU0106261372.USD","LU2552382215.SGD","IE00BFSS7M15.SGD","LU2360106947.USD","LU0079474960.USD","LU0114720955.EUR","LU0094547139.USD","LU0640476718.USD","LU0882574139.USD","LU1232071149.USD","LU2491050071.SGD","SG9999014914.USD","IE00BWXC8680.SGD","LU0203202063.USD","LU0708995401.HKD","LU2471134952.CNY","BK4588","SG9999015986.USD","LU1291159041.SGD","IE00BN29S564.USD","LU2237438978.USD","LU0471298777.SGD","LU1989771016.USD","LU2028103732.USD","LU2271345857.HKD","LU2361045086.USD","LU2462157665.USD","LU0225283273.USD","IE0004445015.USD","LU0466842654.USD","LU1868837300.USD","LU0256863811.USD","IE00B2B36J28.USD","LU1988902786.USD","LU2237443465.HKD","IE00B4R5TH58.HKD","LU2106854487.HKD","LLY","LU0353189680.USD","LU0210536198.USD","IXJ","LU0354030511.USD","LU2461242641.AUD","LU2087625088.SGD","BK4585","IE00BK4W5M84.HKD","LU0943347566.SGD","LU1366192091.USD","LU0385154629.USD","LU2237443622.USD","SG9999014880.SGD","SGXZ31699556.SGD","LU2213496289.HKD","LU2491050154.USD","SG9999013999.USD","SG9999015945.SGD","LU0823434740.USD","LU1623119135.USD","BK4599","LU1868836757.USD","IE0009355771.USD","IE0002141913.USD","LU2746668461.USD","LU0266013472.USD","LU0234572021.USD","LU1323610961.USD","LU1804176565.USD","SG9999018857.SGD","LU0672654240.SGD","LU1267930730.SGD","LU2896262040.SGD","IE00BJLML261.HKD","LU2168563687.JPY","LU2168564495.EUR","IE00BKDWB100.SGD","LU2265009873.SGD","ROIV","IE00B775H168.HKD","IE00BJJMRX11.SGD","LU1093756325.SGD","LU0122379950.USD","SGXZ99366536.SGD","LU2471134879.HKD","SG9999001176.USD","IE0001KFT4U8.USD","LU1069344957.HKD","SG9999017495.SGD","LU2089283258.USD","IE00BFSS8Q28.SGD","LU1061106388.HKD","LU0058720904.USD","IE00BJT1NW94.SGD","LU0787776722.HKD","LU2750360641.GBP","LU2361044865.SGD","LU0203201768.USD","LU2112291526.USD","LU2237443895.HKD","LU0158827781.USD","LU1974910355.USD","LU1145028129.USD","LU0823434583.USD","SG9999001176.SGD","LU0820561818.USD","LU2602419157.SGD","LU1093756168.USD","LU0786609619.USD","LU2023250504.SGD","LU2552382132.HKD","LU0471298694.HKD","LU2237443549.SGD","IE00BFTCPJ56.SGD","BK4533","BK4581","LABU","LU0323591593.USD","BK4550","LU1720051017.SGD","LU2756315664.SGD","LU0158827948.USD","LU0820562030.AUD","LU1023059063.AUD","LU0417517546.SGD","IE00BK4W5L77.USD","BK4534","LU0823416689.USD","LU0354030438.USD","BK4516","LU1280957306.USD","LU2089984988.USD","LU1868836914.USD","LU1868836591.USD","LU2468319806.SGD","LU1720051108.HKD","SGXZ81514606.USD","SGXZ57979304.SGD","LU0109391861.USD","LU2471134796.USD","LU0820561909.HKD","IE00BJJMRZ35.SGD","LU2168564065.EUR","SG9999014906.USD","IE00B1BXHZ80.USD","LU0320765059.SGD","LU1035775433.USD","SG9999015978.USD","LU2264538146.SGD","LU1548497426.USD","LU0096364046.USD","LU0456855351.SGD","LU0689472784.USD","IE0005OL40V9.USD","LU1712237335.SGD","SGXZ51526630.SGD","LU2456880835.USD","LU1057294990.SGD","LU0432979614.USD","IE00BJJMRY28.SGD","IE0004445239.USD","LU0006306889.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624685758","title":"BRIEF-Ro Says Working With Eli Lilly To Launch Zepbound Kwikpen Nationwide On Its Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2624685758","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624685758?lang=en_us&edition=fundamental","pubTime":"2026-04-03 01:08","pubTimestamp":1775149715,"startTime":"0","endTime":"0","summary":"BRIEF-Ro Says Working With Eli Lilly To Launch Zepbound Kwikpen Nationwide On Its PlatformApril 2 (Reuters) - Ro:RO: WORKING WITH ELI LILLY TO LAUNCH ZEPBOUND KWIKPEN NATIONWIDE ON ITS PLATFORM ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"80f30c1ff97a0a0fa49b25c6b2ccdaf7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L10E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ81514606.USD","LU1232071149.USD","LU1868836757.USD","LU2417539215.USD","LU2461242641.AUD","SG9999018857.SGD","BK4599","BK4585","LU0823434583.USD","BK4007","IE00BK4W5L77.USD","LU0203202063.USD","LU2108987350.USD","LU0238689110.USD","LU2552382215.SGD","LU1548497426.USD","LU0114720955.EUR","LU2471134952.CNY","LU2168564149.EUR","BK4581","LU1127390331.HKD","LU1629891620.HKD","LU2237443382.USD","LU2237443465.HKD","LU2552382132.HKD","LU0225283273.USD","LU2756315664.SGD","LU0256863902.USD","IE00B775H168.HKD","IE00BJT1NW94.SGD","LU0094547139.USD","BK4534","LU2471134879.HKD","IE00B2B36J28.USD","LU1291159041.SGD","IE00BFSS8Q28.SGD","IE00BJJMRZ35.SGD","LU0158827948.USD","LU2168564495.EUR","LU2023251221.USD","LU2236285917.USD","GB00BDT5M118.USD","LU0820562030.AUD","IE0002141913.USD","LU2491050154.USD","LU1988902786.USD","SG9999018865.SGD","LU0079474960.USD","LU1267930730.SGD","LU2237438978.USD","LU2265009873.SGD","LU2237443978.SGD","LU2750360997.AUD","LU0964807845.USD","SG9999014906.USD","LU2063271972.USD","LU2111349929.HKD","LU0417517546.SGD","LU0466842654.USD","LU2361044949.HKD","LU2112291526.USD","LU2750360641.GBP","BK4588","IE00B4JS1V06.HKD","LU1069344957.HKD","LU1551013342.USD","LU1093756168.USD","SG9999015986.USD","SG9999015945.SGD","LLII","LU0097036916.USD","LU0158827781.USD","IE00BN29S564.USD","LU1720051017.SGD","LU2746668974.SGD","SG9999015952.SGD","LU0672654240.SGD","LU2168564222.USD","LU2471134796.USD","SG9999017495.SGD","LU0109394709.USD","ELIS","LU2028103732.USD","LU0882574139.USD","LU0198837287.USD","LU0471298777.SGD","LU0385154629.USD","LU0320765992.SGD","LU2491050071.SGD","LU2468319806.SGD","IE0001KFT4U8.USD","IE00BJJMRY28.SGD","LU1023059063.AUD","LU2462157665.USD","IE0004445239.USD","IE0009355771.USD","LU1814569148.SGD","LU2361045086.USD","IE00B1XK9C88.USD","SG9999014880.SGD","LU0456855351.SGD","LU1868837300.USD","LU2602419157.SGD","LU1064131342.USD","LU0820561909.HKD","LU2896262040.SGD","LU2089283258.USD","LLYZ","LU2089284900.SGD","LU0106261372.USD","LU0266013472.USD","LU0109391861.USD","LU2211815571.USD","LU0787776722.HKD","LU0823434740.USD","IE00BJLML261.HKD","LU1989771016.USD","LU0820561818.USD","LU0353189763.USD","LU0234572021.USD","LU1983299246.USD","LU0316494557.USD","SG9999015978.USD","LU0006306889.USD","LU2361044865.SGD","LU0471298694.HKD","LU0320765059.SGD","LU0786609619.USD","LU2357305700.SGD","LU2471134523.USD","LU2237443895.HKD","LLY","IE00BFSS7M15.SGD","LU1145028129.USD","IE0004445015.USD","BK4533","LLYX","LU1280957306.USD","LU2106854487.HKD","IE00BWXC8680.SGD","LU1323610961.USD","LU2168563687.JPY","LU2271345857.HKD","IE00BKPKM429.USD","LU1720051108.HKD","LU1917777945.USD","LU2746668461.USD","SGXZ51526630.SGD","LU0432979614.USD","LU1804176565.USD","LU0943347566.SGD","IE00BK4W5M84.HKD","LU1712237335.SGD","LU1061106388.HKD","LU0354030511.USD","LU2087625088.SGD","BK4516","IE00BJJMRX11.SGD","LU1868836914.USD","LU2023250504.SGD","LU0889565916.HKD","LU2264538146.SGD","LU0203201768.USD","SGXZ31699556.SGD","SGXZ57979304.SGD","LU2213496289.HKD","IE0005OL40V9.USD","LU0882574055.USD","LU0683600562.USD","SG9999001176.USD","LU2360106947.USD","IE00BKDWB100.SGD","LU1366192091.USD","IE00B1BXHZ80.USD","IE00B7KXQ091.USD","LU0323591593.USD","IE00B4R5TH58.HKD","LU0823416689.USD","LU2552382058.USD","LU2456880835.USD","LU1551013425.SGD","LU2237443549.SGD","LU0058720904.USD","SGXZ99366536.SGD","ELIL","LU1035775433.USD","LU0289739699.SGD","LU0353189680.USD","LU2756315318.SGD","LU0708995401.HKD","LU0640476718.USD","LU2023250330.USD","IE00BFTCPJ56.SGD","LU2491049909.HKD","LU0354030438.USD","LU1974910355.USD","SG9999014914.USD","LU0210536198.USD","SG9999013999.USD","LU2089984988.USD","LU1623119135.USD","LU1868836591.USD","LU2237443622.USD","SG9999014898.SGD","LU0689472784.USD","LU2324357040.USD","SG9999001176.SGD","LU1868837136.USD","LU0096364046.USD","LU2168564065.EUR","ROIV","LU1093756325.SGD","LU0061475181.USD","LU0256863811.USD","LU0122379950.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624749195","title":"Immunovant says Phase 3 batoclimab trials miss primary endpoint in thyroid eye disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2624749195","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624749195?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120441,"startTime":"0","endTime":"0","summary":"Immunovant reported topline results from two Phase 3 studies of batoclimab in thyroid eye disease, with results already presented in this update.Both trials missed primary endpoint, raising uncertainty around batoclimab commercial prospects in thyroid eye disease.Safety profile matched prior studies, with no new safety signals flagged.Immunovant shifted emphasis to IMVT-1402 development across autoimmune diseases, with Graves’ disease positioned as key priority.Topline data from potentially registrational IMVT-1402 studies in Graves’ disease expected in calendar year 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3Mp9Mk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","BK4585","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210150020.SGD","BK4007","IE00BN0W2V16.EUR","IE00BKPKM429.USD","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014039.USD","BK4112","IE00BGHQF748.EUR","IMVT","ROIV","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574917","title":"Roivant’s Priovant starts Phase 2b/3 brepocitinib trial in lichen planopilaris","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624574917?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120428,"startTime":"0","endTime":"0","summary":"Priovant, backed by Roivant, began enrolling subjects in a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, with first patients enrolled in March 2026.Prior results have already been reported from an investigator-initiated, placebo-controlled study that supported moving brepocitinib into rapid development for this indication.Program targets a scalp disorder that can cause generally irreversible scarring hair loss with significant pain and itching, with no FDA-approved treatments.Expansion adds a fourth late-stage indication for brepocitinib, extending strategy to build a multi-indication rare rheumatology-dermatology franchise ahead of an expected dermatomyositis launch in September.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLb6YlNB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","NDAQ","BK4007","SG9999014005.SGD","BK4588","SG9999014021.USD","BK4585","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","ROIV","BK4139","IE00BN0W2T93.GBP","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624749355","title":"Roivant Sciences Ltd - Phase 3 Studies of Batoclimab in Ted Fail to Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2624749355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624749355?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUAB6H0NC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624741995","title":"Roivant Sciences Ltd: Topline Phase 3 Data in Niu and Phase 3 Study Initiation in Cs Are Expected in Second Half of Calendar Year 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624741995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624741995?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUAB6H0NC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574508","title":"Roivant Announces Expansion of Brepocitinib Development Program With New Phase 2B/3 Trial in Lichen Planopilaris (Lpp) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (Ted)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574508","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624574508?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUAB6H0NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574186","title":"Roivant Sciences Ltd - Ted Study Patients Show Greater Proptosis Improvement After High-Dose Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624574186?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUAB6H0NC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373281","title":"Roivant director Meghan FitzGerald disposes of common shares worth $1.92 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373281","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623373281?lang=en_us&edition=fundamental","pubTime":"2026-03-31 09:01","pubTimestamp":1774918916,"startTime":"0","endTime":"0","summary":"Roivant Sciences director Meghan FitzGerald sold 70,000 common shares on March 26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLYdstf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant director Meghan FitzGerald disposes of common shares worth $1.92 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623142023","title":"S&P 500 Futures Climb In Premarket Trading; United Therapeutics, Alcoa Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2623142023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623142023?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:31","pubTimestamp":1774870260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, United Therapeutics Corp.  was up 12.9% in pre-market trading, and Alcoa Corp.  was up 9.3%.Semtech Corp. , Roivant Sciences Ltd. , and Spire Inc.  were all posting gains of at least 5%. In early trading, Restaurant Brands International Inc.  and Brixmor Property Group Inc.  had posted declines, falling 6.4% and 6.4%, respectively.Meanwhile S&P 500 futures were up 0.58%, with futures for the Dow Jones Industrial Average rising 0.57%. The Cboe Volatility Index futures were up 9.56%.In commodities news, Brent crude oil futures were up 1.96%, and gold futures were up 0.97%. Bitcoin climbed 1.90% to $67,547.In afternoon trading, stocks in Europe are up, with the STOXX Europe 600 Index climbing 0.44% and the FTSE 100 Index rising 0.80% from the previous close.U.S. stock markets open for trading at 9:30 a.m. ET.Data source: Dow Jones Market Data, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPHQ","VTV","BK4559","BK4141","BK4534","BK4153","BK4585","AA","BK4209","LU2543165471.USD","SMTC","SPXS","BRX","UPRO","IVV","IVW","BK4504","VTI","SH","VEU","BK4007","SPYI","BK4581","SPYD","XYLD","ROIV","SPYG","BK4139","LU1571399168.USD","SPLV","SPMO","SPDN","ACWI","HIBL","BK4588","LU1699723380.USD","MOAT","SPHD","LU0106261612.USD","SPYQ","BK4080","BK4231","XDTE","BK4197","GPIX","ALLW","ETFT","SPUS","SR","DBSC","BK4532","NOBL","OEX","BMAY","SPYM","MESmain","QSR","BK4550","RSP","SDS","LU0012050646.USD","SSO","ESmain","SPXL","JEPI","OEF","SPUU","UTHR","IVE","SPYV","SPXU","IVOO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623354550","title":"Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2623354550","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623354550?lang=en_us&edition=fundamental","pubTime":"2026-03-29 23:08","pubTimestamp":1774796926,"startTime":"0","endTime":"0","summary":"Why the brepocitinib data matters for Roivant Sciences (ROIV)\nThe Phase 3 VALOR trial results for brepocitinib in dermatomyositis, published in the New England Journal of Medicine and paired with an FDA Priority Review, put a key Roivant Sciences (ROIV) asset firmly in focus for investors.\nSee our latest analysis for Roivant Sciences.\nRoivant’s recent brepocitinib milestones arrive after a 1 year total shareholder return of 155.49% and a 3 year total shareholder return of 259.35%. The share...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/assessing-roivant-sciences-roiv-valuation-after-brepocitinib","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/assessing-roivant-sciences-roiv-valuation-after-brepocitinib","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623338960","title":"BRIEF-New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2623338960","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623338960?lang=en_us&edition=fundamental","pubTime":"2026-03-29 03:26","pubTimestamp":1774726019,"startTime":"0","endTime":"0","summary":"BRIEF-New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In DermatomyositisMarch 28 (Reuters) - Roivant Sciences Ltd ROIV.O:NEW ENGLAND JOURNAL OF MEDICINE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nTUA7Q9L0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623388803","title":"Roivant’s brepocitinib beats placebo in Phase 3 dermatomyositis trial, NEJM reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2623388803","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623388803?lang=en_us&edition=fundamental","pubTime":"2026-03-29 03:00","pubTimestamp":1774724430,"startTime":"0","endTime":"0","summary":"Roivant reported New England Journal of Medicine publication of Phase 3 VALOR results for brepocitinib in adults with dermatomyositis.Trial met primary endpoint, with brepocitinib 30 mg once daily delivering 15.3-point greater improvement in mean Total Improvement Score at Week 52 versus placebo .Data showed clinically meaningful steroid-sparing effect, with nearly twice as many patients reducing background corticosteroids in brepocitinib 30 mg group versus placebo.Safety profile showed higher serious infection rate with brepocitinib 30 mg versus placebo, while discontinuations were more frequent on placebo.Additional VALOR analyses were already presented at 2026 American Academy of Dermatology meeting; FDA granted Priority Review with PDUFA target action date in Q3 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL3JjHDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NDAQ","LU2210150020.SGD","BK4585","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","ROIV","IE00BN0W2W23.USD","BK4588","IE00BGHQF748.EUR","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4007","LU0314104364.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.0574},{"period":"1month","weight":0.073},{"period":"3month","weight":0.2897},{"period":"6month","weight":0.7283},{"period":"1year","weight":1.9389},{"period":"ytd","weight":0.3747}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.029395},{"month":5,"riseRate":0.4,"avgChangeRate":0.032328},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}